Peer-reviewedCC BY-NC-NDJAMA health forum
Savings Across Drugs Under the GENEROUS Model in the US Medicaid Program.
- 1Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Related
- Cuts to Medicaid Adult Dental Benefits and Savings for US States
- Comparative risk of injury among users of benzodiazepines and related drugs concomitantly with clarithromycin versus azithromycin: a retrospective cohort study of US Medicaid enrollees.
- Combined Use of Topic-Analysis and LLMs on Online Peer-to-Peer Medicaid Discussions to Detect the Impact of HR1 on Individuals Medicaid Experience Across The US
- Prescription denials for GLP-1 receptor agonists across commercial, Medicare, and Medicaid coverage, 2018-2024.
- Data integration across care settings: HCV monitoring among people who use drugs
BibTeX
@article{ballreich2026savings,
title = {{Savings Across Drugs Under the GENEROUS Model in the US Medicaid Program.}},
author = {Jeromie Ballreich and Nathan Jibat and Tucker Desmond and Joseph Levy},
journal = {JAMA health forum},
year = {2026},
month = oct,
doi = {10.1001/jamahealthforum.2026.3983},
url = {https://europepmc.org/article/MED/42912383},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Savings Across Drugs Under the GENEROUS Model in the US Medicaid Program.
AU - Jeromie Ballreich
AU - Nathan Jibat
AU - Tucker Desmond
AU - Joseph Levy
PY - 2026
DA - 2026/10/02
JO - JAMA health forum
DO - 10.1001/jamahealthforum.2026.3983
UR - https://europepmc.org/article/MED/42912383
SN - 2689-0186
ER -